Multicentric trial compares Oxytocin, Carbetocin, and Misoprostol for atonic Postpartum Hemorrhage treatment

Postpartum hemorrhage (PPH) is the leading cause of maternal death globally, responsible for an estimated 140,000 fatalities annually. A significant contributor to PPH is uterine atony, where the uterus fails to contract adequately after childbirth. Traditional treatment relies on uterotonic agents, with Oxytocin being the most conventional and proven effective. However, Oxytocin has limitations, including a short half-life and the requirement for intravenous administration. Misoprostol and, more recently, Carbetocin have emerged as potential alternatives for atonic PPH not responding to Oxytocin, offering different pharmacokinetic profiles and administration routes.

This study is designed as a multicentric randomized trial to compare the effectiveness of three uterotonic agents for treating atonic Postpartum Hemorrhage (PPH). The interventions under investigation are Oxytocin, Carbetocin, and Misoprostol. The primary objective is to evaluate the efficacy of these drugs in managing PPH caused by uterine atony. Specific details regarding patient enrollment (n), dosing regimens, routes of administration, frequency, duration of treatment, or primary endpoints were not provided in the abstract.

The provided abstract outlines the aim and background of the study but does not contain any results or findings. Therefore, specific data points, statistical analyses, or comparative outcomes between Oxytocin, Carbetocin, and Misoprostol for the treatment of atonic Postpartum Hemorrhage (PPH) are not available in this record. The study's objective is to evaluate the effectiveness of these agents, but the outcomes of this evaluation are not presented here.